<i>TOLLIP</i> , <i>MUC5B</i> , and the Response to <i>N</i> -Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis

Abstract

NAC may be an efficacious therapy for individuals with IPF with an rs3750920 (TOLLIP) TT genotype, but it was associated with a trend toward harm in those with a CC genotype. A genotype-stratified prospective clinical trial should be conducted before any recommendation regarding the use of off-label NAC to treat IPF.